Pharma Focus Asia
KP - Sustainable Packaging Solutions

Novel Repotrectinib Therapeutic Option Discovered for Advanced Solid Tumors

Turning Point Therapeutics, Inc discovered novel repotrectinib, a leading drug candidate for the treatment of patients with advanced solid tumors having an NTRK gene fusion.

Repotrectinib is a therapeutic option for patients who have shown progress with 1 or 2 prior TRK TKIs after treatment, with or without prior chemotherapy and for patients who remain with no other options.

Repotrectinib consists of a small macrocyclic TKI of ROS1, TRK, and ALK. It is bind with the active kinase conformation and avoids steric interference from several clinically-resistant mutations.

Repotrectinib has also been granted an Orphan Drug designation in 2017. U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to lead drug candidate, repotrectinib for the treatment of TKI-pretreated advanced solid tumors.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?